Antibe Therapeutics Inc(Pre-Merger) ATBPF

Canaccord rating - raised to $15, Buy

[Dunworkin2]

* Canaccord Genuity analyst Tania Gonsalves raised her Antibe Therapeutics Inc. (ATE-T) target to $15 from $14.50, exceeding the $14.55 average, with a “speculative buy” rating.

[bigmack1]

I EVER there was a strong spec buy, I believe we have one. Love the price, love the run that this is setting up for! imo 

[Forestview]

What's the timeline?  Not sure I fully support a biased view like Cannacord.  Like many here, it'd be great to just get to $10 and stay there...no more of this one step forward two steps back stuff.  But, I do think it'll breakthrough...just not sure when.

[MrMugsy]

Agree Bigmack. Upset shareholders need to put their vote to work on August 19. Should be interesting to see how many will bring it to the AGM - vote should tell how much is real and how much is just hot air. ------------------ Analysts should be excited ... 1.  Breakthrough Science 2.  Proven Safety and Efficacy 3.  Huge Pipeline - four drugs in markets of $50B+ 4.  Broad IP

[topadvisor1]

This post has been removed in accordance with Community Policy

[Fotoforester]

Incorrect, 4 USD is not necessarily the minimum requirement if they meet other criteria.

[MrMugsy]

In February, we were at $7. May before that we were closer to $8. A big deal could put a few hundred million in the bank immediately. We could also wait for what seems an eterinty. That's the exciting part. Looking for the wording of the July update (specifically w.r.t. NASDAQ) to add a little more colour.

[Inthepez]

“Add a little more colour”. That’s a dan-ism. you are Dan lol

[MrMugsy]

Haha - lucky for me - Dan wasn't the first or the only one to use it.

[Inthepez]

I’m just teasing. But Dan uses that phrase frequently in these interviews lol.